Last reviewed · How we verify

NCT06301776

A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

Recruiting now NA Last updated 8 March 2024
What this trial tests

NA trial testing Ticagrelor in Brain Disease in 560 participants. Currently enrolling.

Timeline
5 December 2023
Primary endpoint
31 December 2025
30 June 2026

Quick facts

Lead sponsorThe Fourth Affiliated Hospital of China Medical University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment560
Start date5 December 2023
Primary completion31 December 2025
Estimated completion30 June 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Fourth Affiliated Hospital of China Medical University

Who can join

Adults 18 to 80, any sex, with Brain Disease or Vertebral Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ticagrelor

Trials testing the same drug.

Other recruiting trials for Brain Disease

Currently open trials in the same condition.

Other The Fourth Affiliated Hospital of China Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06301776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing